BioDlink (Stock Code: 1875.HK) is dedicated to becoming the industry leading and trusted biopharmaceutical best partner for global clients.
With extensive practical experience, mature technical platforms and robust quality system, BioDlink has developed diversified strategic partnerships with domestic and international pharmaceutical companies to provide one-stop CDMO solutions for drug development and manufacturing, which help customers to accelerate the development and manufacturing of biologics, especially antibody-drug conjugates (ADCs), empowering to achieve high-quality development for the industry.
BioDlink has established a large-scale commercial GMP production base for biological drugs which has equipped with multiple complete upstream and downstream production lines, with a total manufacturing capacity exceeding 20,000 L. The company has established an integrated platform for antibody-drug conjugates (ADCs), which can complete key production processes such as antibodies, linker and drug substance to be completed in one place, reducing transfer costs and regulatory risks. Currently, BioDlink has established a quality management system in line with commercial manufacturing, which has successfully supported the commercial production of several marketed products. BioDlink has a mature, stable core team and good reputation for professional, which can provide customers with excellent professional services.